BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB.
- DOI
- 10.1016/j.cellsig.2012.09.008
- Published
- 2013 Jan
- Container
- Cellular signalling
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.cellsig.2012.09.008,
title = {BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB.},
author = {Rushworth SA and Bowles KM and Barrera LN and Murray MY and Zaitseva L and MacEwan DJ},
year = {2013},
journal = {Cellular signalling},
doi = {10.1016/j.cellsig.2012.09.008},
url = {https://doi.org/10.1016/j.cellsig.2012.09.008}
}RIS
TY - JOUR TI - BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB. AU - Rushworth SA AU - Bowles KM AU - Barrera LN AU - Murray MY AU - Zaitseva L AU - MacEwan DJ PY - 2013 JO - Cellular signalling DO - 10.1016/j.cellsig.2012.09.008 UR - https://doi.org/10.1016/j.cellsig.2012.09.008 ER -
APA
SA, R., KM, B., LN, B., MY, M., L, Z., & DJ, M. (2013). BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB.. Cellular signalling. https://doi.org/10.1016/j.cellsig.2012.09.008
Source records
- pubmed · retrieved 2026-09-25T06:14:09.228Z